Literature DB >> 35991253

Clinicopathological features and prognostic factors for uterine myoma.

Xiaoli Wu1, Yanqing Zheng2.   

Abstract

Objectives: To investigate the clinicopathological features of patients with uterine myoma and to analyze and summarize factors affecting patient prognosis.
Methods: This study retrospectively investigated records of uterine myoma patients treated at Huzhou Central Hospital between June 2018 and May 2020. A total of 149 patients were included in this study, including 121 patients with good prognosis and 28 patients with poor prognosis. Clinical and pathological characteristics, including age, average body mass index (BMI), menopausal status, average lesion diameter, presence of hypertension or diabetes mellitus, operation method, myoma type, location, and quantity, number of fibroids, and presence of pelvic adhesion were analyzed via multivariate analysis.
Results: Among the 149 patients with uterine uterine myoma, 92 had anterior wall uterine myoma, 36 had posterior wall uterine myoma, and 21 had uterine fundus uterine myoma. In terms of location, 94 cases were intramural and 55 cases were subserosal. Quantity-wise, 107 had 1-3 myomas while 42 had four or more. Moderate or more severe pelvic adhesions were present in 33 cases. Univariate analysis showed significant differences in age, operation method, myoma type, myoma location, myoma number, and pelvic adhesion severity between patients with good and poor prognosis. Multivariate analysis showed that age, surgical method, uterine myoma type, uterine myoma location, uterine myoma quantity, and pelvic adhesion severity were risk factors affecting the prognosis.
Conclusion: Many prognostic factors, including age, operation method, myoma type, myoma location, myoma number, and pelvic adhesion severity are linked to uterine myoma patient prognosis. Copyright: © Pakistan Journal of Medical Sciences.

Entities:  

Keywords:  Enucleation of Uterine myoma; Pelvic Adhesion; Prognostic Risk Factors; Total Hysterectomy; Uterine myoma

Year:  2022        PMID: 35991253      PMCID: PMC9378402          DOI: 10.12669/pjms.38.6.5455

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   2.340


INTRODUCTION

Uterine myoma, also known as leiomyoma or fibroids, is the most common benign tumor of the female reproductive system. uterine myoma patients generally show no initial obvious signs, but aging can bring abnormal uterine bleeding, pelvic compression symptoms, pain, and impacted fertility. uterine myoma is the main underlying cause for clinical hysterectomy, which in turn has a significant adverse impact on women’s reproductive health, social and medical resource consumption, and the health economy at large. At present, the specific pathogenic mechanism of uterine fibroids is not well known but is believed to be related to a variety of factors, including diet, age, hypertension, diabetes, sex hormone levels, and familial genetics. uterine myoma is mostly treated with surgery,1 such as open uterine myoma enucleation, laparoscopic uterine myoma enucleation, open total hysterectomy, and laparoscopic total hysterectomy. However, these different surgical methods have different therapeutic effects and different prognoses.2,3 As such, this study reviewed the clinicopathological features of uterine myoma patients and analyzed factors potentially impacting patient prognosis.

METHODS

This study retrospectively investigated clinical records of uterine myoma patients treated at Huzhou Central Hospital between June 2018 and May 2020. A total of 149 patients were included, featuring 121 patients with good prognosis and 28 patients with poor prognosis.

Inclusion criteria:

• Presence of a complete clinical history and obvious clinical manifestations. • uterine myoma diagnosis

Exclusion criteria:

• Abnormal blood coagulation. • Presence of severe infectious diseases and malignancies. • Presence of severe abnormalities in cardiopulmonary function or liver and kidney function. This study was approved by the medical ethics committee of Huzhou Central Hospital (Approval number: L210517, Date: 2021 May 28).

Data on the following variables were collected:

age, BMI, menopausal status, lesion average diameter, presence of hypertension or diabetes mellitus, operation method, myoma type and location, presence and number of uterine fibroids, and pelvic adhesion information. Data was analyzed using SPSS 22.0 statistical software. Counting data were expressed as [n (%)] and compared using χ2 tests, while factors affecting patient prognosis were analyzed by multivariate logistic regression. P values less than 0.05 were considered statistically significant.

RESULTS

Patient age ranged from 32 to 75 years, with an average age of 60.83±8.76 years. The mean BMI was 23.9±1.38 kg/m2. Average lesion diameter was 42.13±4.11 mm. Of the 149 total patients, 29 underwent open myomectomy, 51 underwent laparoscopic myomectomy, 23 underwent open hysterectomy, and 46 underwent laparoscopic hysterectomy. Anterior wall myoma was found in 92 cases, posterior wall myoma in 36 cases, and fundus myoma in 21 cases. Regarding myoma location, 94 cases were intramural and 55 cases were subserosal. Myoma count was three or less in 107 cases and four or more in 42 cases. Mild or less severe pelvic adhesions were found in 116 cases and moderate or more severe pelvic adhesions were found in 33 cases. Of all the patients, 121 had good prognosis and 28 had poor prognosis. No significant difference in average BMI, average lesion diameter, or hypertension and diabetes mellitus incidences was noted between patients with good and poor prognosis. However, significant differences were found for age, operation method, myoma type, myoma location, myoma count, and pelvic adhesion severity between the two groups (Table-I). Age, operation method, myoma type, myoma location, myoma number, and pelvic adhesion severity were found to be risk factors affecting uterine myoma prognosis (Table-II).
Table I

Univariate analysis of related factors affecting the prognosis of uterine myoma (n).

FactornGood prognosis group (n=121)Poor prognosis group (n=28)χ²P
Age≥60 years72472523.169<0.001
<60 years77743
BMI≥24 kg/m²9574190.2510.617
<24 kg/m²54459
Menopausal statusYes124101230.0290.865
No25205
Diameter of lesion≥40mm11491230.6090.435
<40mm35305
HypertensiveYes241860.7220.395
No12510322
Diabetes mellitusYes161420.4650.495
No13310726
Operation methodOpen myomectomy29171240.169<0.001
Laparoscopic enucleation of uterine myoma51492
Open hysterectomy231112
Laparoscopic total hysterectomy46442
Myoma typeAnterior wall92821036.715<0.001
Posterior wall36324
Fundus uteri21714
Myoma locationIntramural94692510.1620.001
Subserosal55523
Number of myomas1-3107100737.326<0.001
≥4422121
Pelvic adhesionNone to mild116108848.564<0.001
Moderate to severe331320
Table II

Multivariate analysis of related factors affecting the prognosis of uterine myoma.

FactorBS.E.WalddfPOR95%CI
Age-2.10.7627.58810.0060.1220.027~0.546
Operation mode-0.6360.2974.58910.0320.530.296~0.947
Myoma type1.0690.3947.3710.0072.9111.346~6.296
Myoma location2.2170.7688.33610.0049.1792.038~41.342
Number of myomas-1.790.638.08510.0040.1670.049~0.573
Pelvic adhesion-2.3130.68511.40510.0010.0990.026~0.379
Univariate analysis of related factors affecting the prognosis of uterine myoma (n). Multivariate analysis of related factors affecting the prognosis of uterine myoma.

DISCUSSION

Morphologically, uterine myomas are mainly composed of connective tissue and smooth muscle. Since it can involve parts of the endometrium, uterine myoma may also lead to pathological changes, such as endometrial hyperplasia and endometrial cancer.4 Pharmacological interventions are restricted to growth inhibition rather than tumor removal, and surgery is still a preferred method of uterine myoma treatment.5,6 Hysterectomy is considered a traditional surgical intervention for uterine myoma, but the severity of this option has driven researchers to search for alternative options.7,8 More recently, myomectomy has become prioritized, with the overall goal of preserving uterine integrity. However, although myomectomy has achieved some clinical efficacy, patient prognosis following this procedure still varies.9,10 This shift in clinical intervention policy has also highlighted the importance of early diagnosis using a combination of clinical manifestation information and imaging examinations.11,12 This study showed that age equal to or greater than 60 was a risk factor affecting uterine myoma prognosis. This effect is potentially due to an age-related decline in physical and immune functions that results in a greater risk of endometrial hyperplasia caused by stimulation, as well as in greater physiological impact from surgical intervention. Our results are supported by previous studies. A study of 110 patients with uterine myoma also showed that age was positively correlated with tumor volume,13 while a study of 875 patients with endometrial hyperplasia and 263 patients with endometrial adenocarcinoma concluded that patient age is an important prognostic factor for endometrial cancer that is independent of other parameters.14 This study also found that uterine myoma patient prognosis is worse after open surgery as compared to laparoscopic surgery. Laparoscopic surgery methods are generally considered to be more accurate, leading to less adhesion, less local bleeding, and more thorough flushing of the pelvic and abdominal cavities. A clinical meta-analysis showed that laparoscopic surgery had lower incidence of complications and shorter postoperative hospital stay than laparotomy, furthermore, this analysis found that prognosis for cases involving the posterior wall and fundus was worse than cases involving the anterior wall.15 This is possibly due to the fact that the bladder of the forearm myoma generally needs to be filled to an appropriate filling degree, while the tissues and organs around anterior wall myomas are mainly physiological uterine and bladder tissues located far away from intestine and sacrum, therefore lowering risk of complications.16 This investigation shows that pelvic adhesion is a prognostic factor of uterine myoma, which is consistent with previous studies. Previous study, investigating primary endometrioid carcinoma with and without myometrial infiltration, as well as 20 cases of regional lymph node metastasis found that myometrial infiltration was an independent prognostic parameter of endometrioid carcinoma associated with pelvic and/or paraaortic lymph node metastasis risk.17 Finally, four or more myomas in a patient were found to be a risk factor, probably due to a fact that in cases of multiple myomas, intervention requires more incisions on the surface of the uterus, leading to higher risk of post-operative adhesions.18

Limitations of the study

It must be noted that this study may deviate from other research findings due to a small, ethnically and regionally homogenous patient pool. Multicenter, large sample size, and longer follow-up are needed to better assess patient prognosis.

CONCLUSION

This study analyzed the pathological characteristics of patients with uterine myoma, which may help improve the accuracy of disease diagnosis. Age, operation method, myoma type, myoma location, myoma numbers, and pelvic adhesion are risk factors affecting the prognosis of uterine myoma, and can provide a reference for clinical treatment.

Authors’ contributions:

XW: Conceived and designed the study. XW & YZ: Collected the data and performed the analysis. XW: Was involved in the writing of the manuscript and is responsible for the integrity of the study. All authors have read and approved the final manuscript.
  17 in total

Review 1.  Comparison of laparoscopy and laparotomy for endometrial cancer.

Authors:  Hui Zhang; Jing Cui; Lin Jia; Shuhui Hong; Beihua Kong; Dadong Li
Journal:  Int J Gynaecol Obstet       Date:  2011-12-23       Impact factor: 3.561

2.  [Predisposing factors of hysteromyoma and effect of hualiu recipe on it].

Authors:  Lei Tan; Wei Meng; Ting-ting Zhang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2011-05

Review 3.  Total abdominal hysterectomy.

Authors:  W A Cliby
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1997-03

4.  Clinico-epidemiological study of endometrial hyperplasia--a risk factor for the development of endometrial carcinoma?

Authors:  A Cărăuleanu; Ivona Anghelache Lupaşcu; Daniela Mihaela Cărăuleanu; R Socolov; Demetra Socolov
Journal:  Rev Med Chir Soc Med Nat Iasi       Date:  2015 Jan-Mar

Review 5.  Epidemiology and Risk Factors of Uterine Fibroids.

Authors:  Dora Pavone; Sara Clemenza; Flavia Sorbi; Massimiliano Fambrini; Felice Petraglia
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2017-10-01       Impact factor: 5.237

6.  [Transcervical resection of myoma in treatment of hysteromyoma, experience in 962 x\cases].

Authors:  En-lan Xia; Hua Duan; Xiao-wu Huang; Jie Zheng; Dan Yu
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2005-01-19

Review 7.  [Study of effective components and molecular mechanism for Guizhi Fuling formula treatment of dysmenorrhea, pelvic inflammatory disease and uterine fibroids].

Authors:  Zhi-peng Ke; Xin-zhuang Zhang; Yue Ding; Ze-yu Cao; Na Li; Liang Cao; Tuan-jie Wang; Chen-feng Zhang; Gang Ding; Zhen-zhong Wang; Wei Xiao; Xiao-jie Xu
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2015-03

8.  Correlation between uterine fibroids with various magnetic resonance imaging features and therapeutic effects of high-intensity focused ultrasound ablation.

Authors:  Hailing Cheng; Chen Wang; Jun Tian
Journal:  Pak J Med Sci       Date:  2015 Jul-Aug       Impact factor: 1.088

9.  An unusual extremely distant noncommunicating uterine horn with myoma and adenomyosis treated with laparoscopic hemihysterectomy.

Authors:  Michele Morelli; Roberta Venturella; Rita Mocciaro; Daniela Lico; Fulvio Zullo
Journal:  Case Rep Obstet Gynecol       Date:  2013-09-12

Review 10.  Uterine fibroid management: from the present to the future.

Authors:  Jacques Donnez; Marie-Madeleine Dolmans
Journal:  Hum Reprod Update       Date:  2016-07-27       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.